Pyrogen retention: Comparison of the novel medium cut-off (MCO) membrane with other dialyser membranes.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 26 02 2018
accepted: 03 04 2019
entrez: 3 5 2019
pubmed: 3 5 2019
medline: 24 10 2020
Statut: epublish

Résumé

Haemodialysis effectively removes small solutes and smaller-sized middle molecules from the blood; however, the clearance of larger middle molecules, which have been associated with negative effects, is poor. The novel medium cut-off (MCO) dialysis membrane has larger pore sizes and a more open structure than other high-flux membranes, providing improved removal of larger middle molecules while retaining albumin. However, larger pore sizes may potentially increase permeability to pyrogens, including endotoxins and other bacterial contaminants, that could be present in the dialysis fluid. In this study, we tested the capacity of low-flux, high-flux, MCO and high cut-off dialyser membranes with different pore sizes to prevent pyrogens crossing from dialysate to the blood side in a closed-loop test system, differentiating among lipopolysaccharides, peptidoglycans and bacterial DNA using a toll-like receptor assay. Even though the bacterial contamination levels in our test system exceeded the acceptable pyrogen dose for standard dialysis fluid, levels of lipopolysaccharides, peptidoglycans and bacterial DNA in the blood-side samples were too low to identify potential differences in pyrogen permeability among the membranes. Our results suggest that MCO membranes are suitable for haemodialysis using ISO standard dialysis fluid quality, and retain endotoxins at a similar level as other membranes.

Identifiants

pubmed: 31043670
doi: 10.1038/s41598-019-43161-2
pii: 10.1038/s41598-019-43161-2
pmc: PMC6494805
doi:

Substances chimiques

Albumins 0
Dialysis Solutions 0
Endotoxins 0
Lipopolysaccharides 0
Membranes, Artificial 0
Pyrogens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6791

Références

Sci Rep. 2015 Dec 16;5:18448
pubmed: 26669756
Eur J Immunol. 2001 Jul;31(7):2154-63
pubmed: 11449369
PLoS One. 2017 Jan 13;12(1):e0169024
pubmed: 28085888
J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S274-80
pubmed: 17130274
J Immunol Methods. 2010 Jun 30;358(1-2):93-103
pubmed: 20385141
Blood Purif. 2004;22(1):124-9
pubmed: 14732820
Nephron. 1997;75(4):438-43
pubmed: 9127331
Blood Purif. 2006;24(2):203-11
pubmed: 16373999
J Am Soc Nephrol. 2004 Dec;15(12):3207-14
pubmed: 15579524
Int J Artif Organs. 2013 Jul;36(7):455-63
pubmed: 23661558
Blood Purif. 2011;32(2):112-6
pubmed: 21447946
Am J Kidney Dis. 2002 Sep;40(3):582-9
pubmed: 12200811
Am J Kidney Dis. 2016 Apr;67(4):664-76
pubmed: 26500179
Nephrol Dial Transplant. 2012 Nov;27(11):4010-21
pubmed: 22844107
J Biol Chem. 2001 Jul 13;276(28):25953-8
pubmed: 11337489
Nephrol Dial Transplant. 2009 Feb;24(2):548-54
pubmed: 18768583
Nephrol Dial Transplant. 2007 Jan;22(1):20-3
pubmed: 17035373
Vaccine. 2004 Jun 23;22(19):2494-9
pubmed: 15193414
Nephrol Dial Transplant. 2017 Jan 1;32(1):165-172
pubmed: 27587605
Nephrol Dial Transplant. 2011 Aug;26(8):2624-30
pubmed: 21310741
Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii6-12
pubmed: 11890657
BMC Nephrol. 2018 Jan 5;19(1):1
pubmed: 29304774

Auteurs

Michael Hulko (M)

Baxter International Inc., Research & Development, Holger-Crafoord-Str. 26, 72379, Hechingen, Germany. michael_hulko@baxter.com.

Verena Dietrich (V)

Baxter International Inc., Research & Development, Holger-Crafoord-Str. 26, 72379, Hechingen, Germany.

Ilona Koch (I)

Baxter International Inc., Research & Development, Holger-Crafoord-Str. 26, 72379, Hechingen, Germany.

Alexander Gekeler (A)

Baxter International Inc., Research & Development, Holger-Crafoord-Str. 26, 72379, Hechingen, Germany.

Michael Gebert (M)

Baxter International Inc., Research & Development, Holger-Crafoord-Str. 26, 72379, Hechingen, Germany.

Werner Beck (W)

Baxter International Inc., Research & Development, Holger-Crafoord-Str. 26, 72379, Hechingen, Germany.

Bernd Krause (B)

Baxter International Inc., Research & Development, Holger-Crafoord-Str. 26, 72379, Hechingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH